RxDoctor Payments Data

Hop Dinh, APRN

Family · Celebration, FLNPI 1346723574

Payments from drug & device makers

$371in general payments, 2019–2025

Across 16 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$95
  • Insulet Corporation$48
  • Antares Pharma, Inc.$47
  • Lilly USA, LLC$35
  • Dexcom, Inc.$35
  • AbbVie$31
  • plus $81 from 4 others

What the payments were for

  • Food & beverage$371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$371 in reported general payments places this provider in the 50th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$45,397
Medicare patients
204
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide208$319,510
OzempicSemaglutide177$257,549
TrulicityDulaglutide132$243,680
JardianceEmpagliflozin90$126,221
RybelsusSemaglutide45$80,682
FarxigaDapagliflozin Propanediol45$51,914
Tresiba Flextouch U-100Insulin Degludec26$33,462
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$30,526
Tresiba Flextouch U-200Insulin Degludec21$23,429
Humalog Kwikpen U-100Insulin Lispro48$19,285
Synjardy XrEmpagliflozin/Metformin Hcl13$18,330
TradjentaLinagliptin11$16,969
VascepaIcosapent Ethyl24$15,304
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$14,752
JanuviaSitagliptin Phosphate14$14,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$35$563,190340 claims
Novo NordiskOzempic, Rybelsus$95$338,232222 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$16$161,520114 claims
AbbVieSynthroid$31$5,34757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 14,618 family providers in Florida.

Other family in Celebration

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →